The move also marks a strategic reorganisation. While the new company will focus more strongly on basic innovation and new platform technologies, BioNTech will concentrate its efforts on clinical development and potential market launches. The company expects around 15 ongoing phase three studies in cancer research by the end of 2026 and is thus increasingly positioning itself as a multi-product provider. BioNTech intends to contribute relevant mRNA technologies and rights to the new company in return for a minority stake. In addition, licence payments and possible milestone payments are planned. Both companies will also work together on combination therapies in the future. This is already the third joint biotech company for Sahin and Türeci. After founding Ganymed and BioNTech, they now want to push technological boundaries again and develop new applications for mRNA. A binding agreement is expected to be signed in the first half of the year.
News of "BioNTech SE" from 10 March 2026